- SEQENS and Brenntag form a strategic partnership for non-GMP intermediates distribution in Europe.
- The collaboration aims to improve availability and coverage through Brenntag's logistics expertise.
- Quality assurance will align with SEQENS standards, ensuring traceability and performance.
- The partnership offers a reliable solution for European pharmaceutical non-GMP intermediate needs.
Partnership Overview
SEQENS and Brenntag have established a strategic partnership to distribute non-GMP pharmaceutical intermediates across Europe. This collaboration aims to enhance the availability and distribution of these intermediates, leveraging Brenntag's logistics and commercial expertise.
Quality and Assurance
The partnership ensures that the quality assurance of non-GMP intermediates aligns with SEQENS standards. This alignment guarantees traceability and performance, which are critical in the pharmaceutical industry.
Market Impact
This collaboration provides European pharmaceutical companies with a reliable and competitive solution for their non-GMP intermediate needs. It also optimizes lead times and offers flexibility in responding to market demands.
Strategic Goals
The partnership is part of SEQENS' strategy to maintain proximity to customers and strengthen its presence in the European market. It enables quick responses to market demands while upholding high standards of quality and safety.
